Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Takashi Kawahara a, Tappei Takeshima a, Yasuhide Miyoshi a, Noboru Nakaigawa b, Masahiro Yao b, Mikiko Tanabe c, Hiroji Uemura a

a Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan; b Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; c Division of Diagnostic Pathology, Yokohama City University Medical Center, Yokohama, Japan

Keywords
Pazopanib · Nivolumab · Metastatic renal cell carcinoma

Abstract
COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwent right nephrectomy in 2015. In 2017, iliac bone metastasis was found and consequently lung metastasis was developed. Pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers during pazopanib treatment for more than two years and the size and number of lung metastases decreased. We herein report a case of successful control of metastatic renal cell carcinoma for more than two years using pazopanib treatment.

Introduction
For primary advanced or recurrent metastatic renal cell carcinoma (mRCC), sunitinib and pazopanib are recommended treatment options, especially for favorable and intermediate-
risk RCC, according to the NCCN and EAU guidelines [1–4]. Recently, combination therapy of ipilimumab and nivolumab has prolonged both the progression-free survival (PFS) and overall survival (OS) compared to sunitinib treatment in mRCC and is available for clinical application in Japan [5]. However, despite its effectiveness, ipilimumab and nivolumab combination treatment has a high rate of immune reactive adverse events (irAEs), and around 60% of treated patients must take steroids to manage these irAEs. We herein report a case of successful control of mRCC for more than two years using pazopanib treatment.

Case Presentation

A 70-year-old man underwent chemo-radiotherapy for T4N1M0 lung cancer in October 2014. Follow-up computed tomography (CT) showed a right renal tumor 5.2 cm in size, so he was referred to our hospital for a further examination. Contrast-enhanced CT suggested RCC, so laparoscopic nephrectomy was performed in October 2015 (Fig. 1). A pathological examination revealed clear cell carcinoma, Furman grade 2. In December 2015, fluorodeoxyglucose-positron emission tomography (FDG-PET)-CT showed the uptake of FDG at his left iliac bone, so a bone biopsy was performed (Fig. 2). The pathological diagnosis was bone metastasis from RCC.

Due to the lack of other metastatic lesions, radiotherapy and denosumab treatment were performed. Follow-up CT revealed multiple lung metastases in August 2016, so pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers, including AST, ALT, and gamma GTP, during pazopanib treatment for more than two years, and the size and number of lung metastases decreased (Fig. 3, 4). CT showed no marked changes on his iliac bone metastasis (Fig. 4). We also assessed the PD-L1 expression using immunohistochemistry found expression.

Discussion

The CheckMate-214 study showed that the combination of ipilimumab and nivolumab prolonged the PFS comparing to sunitinib treatment (11.6 vs. 8.4 months, p = 0.033) [5]. While ipilimumab with nivolumab combination therapy and sunitinib treatment have almost the same side effects (Grade ≥3), ipilimumab with nivolumab requires additional steroid treatment for managing irAEs in around 60% of treated patients [5].

The SU11248 study revealed that sunitinib prolonged the PFS compared with interferon alpha (11 vs. 5 months, p < 0.001) [10]. The VEG105192 study showed that pazopanib prolonged the PFS, although no significant difference in the OS was noted (9.2 vs. 4.2 months, p < 0.001 and 22.9 vs. 20.5 months p = 0.224). The COMPARZ study revealed no marked differences in terms of the PFS or OS between sunitinib and pazopanib treatment [6]. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment.

In the CheckMate-214 study, the group with a high PD-L1 expression showed more favorable results when ipilimumab with nivolumab treatment was administered, but even in the low-PD-L1-expression group, ipilimumab with nivolumab showed favorable efficacy [5, 7]. The present case showed a positive expression of PD-L1. In the COMPARZ study, the high-PD-L1-expression group showed a poorer outcome than the low-PD-L1-expression group [8]. While there are no useful biomarkers for predicting whether or not an immune checkpoint
inhibitor will be effective in a given patient, the PD-L1 expression plays an important role in mRCC patients.

In the present case, the patient was able to take a full dose of pazopanib without experiencing any side effects for more than two years, achieving successful cancer control. The VEG105192 studies found median PFS values of 9.2 months [6, 9]. Thus, a PFS exceeding two years is relatively rare. While the combination of ipilimumab and nivolumab has shown a more favorable outcome than treatment with sunitinib in a number of studies, tyrosine kinase inhibitors – including pazopanib and sunitinib – still play an important role in the first-line treatment of mRCC.

Availability of Data and Material

Due to ethical restrictions, the raw data underlying this paper are available upon request to the corresponding author.

Statement of Ethics

Written informed consent to participate in this study and for the publication of this report was obtained from the patient. A copy of the written consent form is available for review from the Editor-in-Chief of this journal. The present study received ethical approval.

Disclosure Statement

The authors declare no conflicts of interest in association with the present study.

References

1. Couldwell WT, Chandrasoma PT, Weiss MH. Pituitary gland metastasis from adenocarcinoma of the prostate. Case report. J Neurosurg. 1989 Jul;71(1):138–40.
2. Tsuzuki T, Iwata H, Murase Y, Takahara T, Ohashi A. Renal tumors in end-stage renal disease: A comprehensive review. Int J Urol. 2018 Sep;25(9):780–6.
3. Ljungberg B, Bensalah K, Canfield S, Daibestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015 May;67(5):913–24.
4. Ohtaka M, Kawahara T, Ishiguro Y, Sharma M, Yao M, Miyamoto H, et al. Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer. Int J Urol. 2018 Oct;25(10):901–2.
5. Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):297–310.
6. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug;369(8):722–31.
7. Yasui M, Kawahara T, Takamoto D, Izumi K, Uemura H, Miyamoto H. Distribution of androgen receptor expression in the urinary bladder. Int J Urol. 2019 Feb;26(2):305–6.
8. Fontán A, Zarranz JJ, Camarero C, Forcadas I. [Dementia caused by miliary cerebral metastasis of a hepatocarcinoma]. Med Clin (Barr). 1989 Oct;93(11):421–3.
9. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013 Apr;49(6):1287–96.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug;27(22):3584–90.
Fig. 1. CT in initial right renal tumor.

Fig. 2. Left iliac bone metastasis in PET-CT.
Fig. 3. Clinical course.

Fig. 4. CT before initial pazopanib treatment (2017/3) as well as 2 months (2017/5) and 2 years (2019/4) after initial pazopanib treatment.